Sonidegib: First Global Approval

Drugs

Volumn 75, Issue 13, 2015, Pages 1559-1566

  Burness, Celeste B ^a  

^a Springer Mairangi Bay 0754 ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; BUPARLISIB; CISPLATIN; CREATINE KINASE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; CYTOCHROME P450 3A4; GEMCITABINE; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOCONAZOLE; LENALIDOMIDE; PACLITAXEL; PHENYTOIN; PROTON PUMP INHIBITOR; RIFAMPICIN; RUXOLITINIB; SAQUINAVIR; SMOOTHENED PROTEIN; SONIDEGIB; SPHINGOSINE KINASE 1; TELITHROMYCIN; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; G PROTEIN COUPLED RECEPTOR; PYRIDINE DERIVATIVE; SMO PROTEIN, HUMAN;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CALORIC INTAKE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONGENITAL MALFORMATION; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EMBRYO DEATH; FAINTNESS; FATIGUE; FETUS DEATH; FOOD; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; LIPID DIET; LIVER CELL CARCINOMA; MEDULLOBLASTOMA; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; NONHUMAN; OVARY CANCER; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SARCOMA; SIDE EFFECT; SMALL CELL LUNG CANCER; SOLID TUMOR; TREATMENT OUTCOME; TUMOR REGRESSION; VOMITING; WEIGHT REDUCTION; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; SKIN NEOPLASMS;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CARCINOMA, BASAL CELL; DRUG APPROVAL; HUMANS; NEOPLASMS; PYRIDINES; RECEPTORS, G-PROTEIN-COUPLED; SKIN NEOPLASMS;

EID: 84941166595     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0458-y     Document Type: Review

References (29)

1. Pramanik D. Development of hedgehog pathway inhibitors (HPI) in treatment of cancer. Curr Chem Biol. 2014;8(3):132-48.
2. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8(10):743-54.
3. Wang C, Wu H, Katritch V, et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature. 2013;497(7449):338-43.
4. ® (sonidegib) capsules, for oral use: US prescribing information. 2015. http://www.accessdata.fda.gov/. Accessed 27 July 2015.
5. ® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer [media release]. 24 July 2015. https://www.novartis.com/news/news-archive.
6. U.S. Food and Drug Administration. FDA approves new treatment for most common form of advanced skin cancer [media release]. 24 July 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm.
7. Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716-28.
8. ® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients [media release] 20 August 2015.
9. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011;131(8):1735-44.
10. Fu J, Rodova M, Nanta R, et al. NPV-LDE-225 (erismodegib) inhibits epithelial mesenchymal transition and self-renewal of glioblastoma initiating cells by regulating miR-21, miR-128, and miR-200. Neuro Oncol. 2013;15(6):691-706.
11. D'Amato C, Rosa R, Marciano R, et al. Inhibition of hedgehog signalling by NVP-LDE225 (erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014;111(6):1168-79.
12. Nanta R, Shankar S, Srivastava RK. NPV-LDE-225 (erismodegib) inhibits human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128 [abstract no. 3193]. Cancer Res. 2013;73(8 Suppl 1). doi: 10.1158/1538-7445.AM2013-3193.
13. Yang S, Brown RD, Loh YS, et al. Blockade of the hedgehog signaling pathway by the novel agent NVP-lde225 induces differentiation, prevents de-differentiation and inhibits proliferation of multiple myeloma stem cells in vitro [abstract no. 3950]. In: 54th ASH annual meeting; 2012.
14. Meng F, Huang K, Jiang X, et al. Hedgehog inhibitor NVP-LDE225 enhances sensitivity of chemoresistant acute myeloid leukemia cells to chemotherapeutics by down-regulating MRP1 via a mechanism involving IGF-1R/PI3K/AKT signaling. Haematologica. 2014;99(Suppl 1):551-2.
15. Fendrich V, Wiese D, Waldmann J, et al. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann Surg. 2011;254(5):818-23.
16. Jalili A, Mertz KD, Romanov J, et al. NVP-LDE225, a potent and selective Smoothened antagonist reduces melanoma growth in vitro and in vivo. PLoS One. 2013;8(7):e69064.
17. Steg AD, Katre AA, Bevis KS, et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther. 2012;11(7):1587-97.
18. Heller E, Hurchla MA, Xiang J, et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012;72(4):897-907.
19. Maier T, Kulichova D, Ruzicka T, et al. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression. J Am Acad Dermatol. 2014;71(4):725-30.
20. Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900-9.
21. Migden M, Lear J, Gutzmer R, et al. Inhibition of the hedgehog pathway with sonidegib (LDE225) in advanced basal cell carcinoma [abstract no. 1373]. J Am Acad Dermatol. 2015;72(Suppl 1):AB186.
22. Zollinger M, Lozac'h F, Hurh E, et al. Absorption, distribution, metabolism, and excretion (ADME) of (1)(4)C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother Pharmacol. 2014;74(1):63-75.
23. Zhou J, Hurth E, Emotte C, et al. Evaluation of CYP3A4 endogenous biomarkers in a sonidegib drug- drug interaction study with rifampicin and ketoconazole in healthy subjects [abstract no. LBI-021]. In: American society for clinical pharmacology and therapeutics annual meeting; 2014.
24. Kieran M, Geoerger B, Casanova M, et al. A phase 1/2 safety and preliminary efficacy study of sonidegib (LDE225), a hedgehog pathway inhibitor, in pediatric and adult patients with relapsed or refractory medulloblastoma and other solid tumors [abstract no. NO-068]. Neurooncology. 2013;15(3):iii115.
25. Gupta V, Koschmieder S, Harrison CN, et al. Phase 1b dose-escalation study of sonidegib (LDE225) in combination with ruxolitinib (INC424) in patients with myelofibrosis [abstract]. In: 56th annual meeting of the American society of hematology; 2014.
26. Pietanza MC, Krug LM, Varghese AM, et al. Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC) [abstract no. 7602]. J Clin Oncol. 2014;32(15 Suppl 1):7602.
27. Ottmann O, Charbonnier A, Steegmann JL, et al. Smoothened (Smo) inhibitor LDE225 combined with nilotinib in patients with chronic myeloid leukemia (CML) resistant/intolerant (R/I) to at least 1 prior tyrosine kinase inhibitor: a phase 1b study [abstract no. P231]. In: European hematology association congress; 2015.
28. Shou Y, Robinson DM, Amakye DD, et al. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015;21(3):585-93.
29. Martin M, Ruiz-Borrego M, Trigo JM, et al. A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study) [abstract no. OT1-1-06]. Cancer Res. 2015;75(Suppl 9). doi: 10.1158/1538-7445.SABCS14-OT1-1-06.